title: Overcoming cellular immunity to prolong adenoviral-mediated gene expression in sciatic nerve.
abstract: In a previous report, we demonstrated that a first generation (E1- and E3-deleted) recombinant adenovirus can transduce expression of the E. coli lacZ gene into Schwann cells, both in vitro and in vivo, suggesting that this method might be useful for future therapy of peripheral neuropathy, including CMT1. Adenoviral-mediated gene transfer was limited, however, by demyelination and Wallerian degeneration at the site of virus injection, as well as by attenuation of viral gene expression over time. In our current work we have optimized adenoviral-mediated gene expression after intraneural injection into sciatic nerve. Using an improved injection protocol, peak expression of lacZ occurs between 10 and 14 days after injection of 2-week-old animals, decreases thereafter, and there is minimal associated tissue injury. In contrast, very few adenoviral-infected Schwann cells are found in nerves of adult animals 10 days after injection, probably due to immune clearance of viral-infected cells. Consistent with this notion, high levels of lacZ are found in sciatic nerve 30 days after injection of adult SCOD mice, which have a genetic defect in both cellular and humoral immunity, of adult beta 2 microglobulin-deficient mice (beta 2 M-/-), which have a genetic defect in cellular immunity, or of adult mice treated with the immunosuppressing agent FK506. In addition, adenoviral-infected Schwann cells co-cultured with axons in vitro, in the absence of a host immune response, ensheath axons and express lacZ for at least 8 weeks. These data thus demonstrate that expression of first generation recombinant adenovirus in sciatic nerve in adult mice, as in other tissues, is limited mainly by the host cellular immune response to the virus, which can be overcome by attenuation of host cell-mediated immunity. Adenoviral vectors might thus be used to modulate Schwann cell gene expression in patients with peripheral neuropathy after appropriate immunosuppression.
authors.affiliation: Department of Neurology, Wayne State University School of Medicine, Detroit, Michigan 48201, USA.
authors.forename: A
authors.initials: A
authors.lastname: Jani
authors.forename: D
authors.initials: D
authors.lastname: Menichella
authors.forename: H
authors.initials: H
authors.lastname: Jiang
authors.forename: T
authors.initials: T
authors.lastname: Chbihi
authors.forename: G
authors.initials: G
authors.lastname: Acsadi
authors.forename: J
authors.initials: J
authors.lastname: Kamholz
authors.forename: M E
authors.initials: ME
authors.lastname: Shy
mesh_terms: D000256:Adenoviridae; D000818:Animals; D002478:Cells, Cultured; D018920:Coculture Techniques; D005727:Ganglia, Spinal / Q000166:cytology / Q000502:physiology; D018014:Gene Transfer Techniques; D005822:Genetic Vectors; D007111:Immunity, Cellular; D051379:Mice; D008807:Mice, Inbred BALB C; D018345:Mice, Knockout; D016513:Mice, SCID; D016133:Polymerase Chain Reaction; D051381:Rats; D017207:Rats, Sprague-Dawley; D011994:Recombinant Proteins / Q000378:metabolism; D012583:Schwann Cells / Q000166:cytology / Q000276:immunology / Q000502:physiology*; D012584:Sciatic Nerve / Q000276:immunology; D001616:beta-Galactosidase / Q000235:genetics* / Q000378:metabolism
chemical_list: D011994:Recombinant Proteins; D001616:beta-Galactosidase